MedTrace Logo

Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy

NCT04966520 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-02-10

No results posted yet for this study

Summary

This project is aimed at the discovery of neuro-modulation techniques that may alleviate chemotherapy induced cognitive deficits (CICD), especially in executive (higher-order) cognitive function (EF).

Conditions

Interventions

OTHER

Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)

Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients. Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be \~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days.

Sponsors & Collaborators

  • American Cancer Society-Holden Comprehensive Cancer Society

    collaborator UNKNOWN

  • Fraternal Order of Eagles (Iowa)

    collaborator UNKNOWN

  • Sneha Phadke

    lead OTHER

Principal Investigators

  • Sneha Phadke, DO · University of Iowa Hospitals & Clinics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-07-18
Completion
2023-07-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966520 on ClinicalTrials.gov